Table 1.
The detail clinical features and the results of univariate and multivariable Cox regression analyses in training cohort.
| Level | Number (%) | Univariate cox analysis | Multivariate cox analysis | |
|---|---|---|---|---|
| p Value | HR (95%CI) | p Value | ||
| Age | ||||
| < 60 | 202 (57.1) | 3.15e−15* | 10.09 (20.93–4.86) | 5.5e−10* |
| ≥ 60 | 152 (42.9) | |||
| Gender | ||||
| Male | 224 (63.3) | 2.74e−04* | 1.49 (2.13–1.04) | 0.03* |
| Female | 130 (36.7) | |||
| T stage | ||||
| T0 | 23 (6.5) | 0.271 | 1.01 (1.46–0.69) | 0.97 |
| T1 | 40 (11.3) | |||
| T2 | 71 (20.1) | |||
| T3 | 80 (22.6) | |||
| T4 | 68 (19.2) | |||
| Tis | 7 (2.0) | |||
| TX | 42 (11.9) | |||
| NA | 23 (6.5) | |||
| N stage | ||||
| N0 | 171 (48.3) | 0.036* | 1 (1.15–0.88) | 0.97 |
| N1 | 65 (18.4) | |||
| N2 | 39 (11.0) | |||
| N3 | 45 (12.7) | |||
| NX | 18 (5.1) | |||
| NA | 16 (4.5) | |||
| M stage | ||||
| M0 | 313 (88.4) | 0.005* | 1.17 (1.37–0.99) | 0.06 |
| M1 | 19 (5.4) | |||
| NA | 22 (6.2) | |||
| Stage | ||||
| I | 74 (20.9) | 0.359 | 1.26 (3.04–0.52) | 0.61 |
| II | 59 (16.7) | |||
| III | 143 (40.4) | |||
| IV | 18 (5.1) | |||
| NA | 60 (16.9) | |||
| Radiation therapy | ||||
| NO | 264 (74.6) | 5.42e−04* | 1.25 (1.64–0.95) | 0.11 |
| YES | 72 (20.3) | |||
| NA | 18 (5.1) | |||
| Disease free survival | ||||
| NO TUMOR | 132 (37.3) | 0.003* | 1.07 (1.61–0.71) | 0.76 |
| TUMOR | 215 (60.7) | |||
| NA | 7 (2.0) | |||
| IRGPI | ||||
| High IRGPI | 192 (54.2) | 0.714 | 2.32 (3.4–1.58) | 1.9e−05* |
| Low IRGPI | 162 (45.8) | |||
| OS status | ||||
| Dead | 186 (52.5) | – | – | – |
| Alive | 168 (47.5) | |||
Abbreviation: HR hazard ratio, CI confidential interval, IRGPI immune-related gene pairs index, OS overall survival.